Skip to main content

Banco Macro Calls Hybrid General Shareholders’ Meeting for April 8, 2026

Tipranks - Thu Feb 26, 4:36PM CST

Claim 50% Off TipRanks Premium

Banco Macro SA ( (BMA) ) has shared an announcement.

Banco Macro SA, through its U.S.-registered entity Macro Bank Inc., reported to regulators that its board of directors met on February 25, 2026, in Buenos Aires. At that meeting, the board decided to convene a general shareholders’ meeting in a hybrid format.

The shareholders’ meeting was scheduled for April 8, 2026, at 11:00 a.m. Buenos Aires time, with both in-person attendance at a designated Buenos Aires address and remote participation via Zoom, in line with the bank’s bylaws. This move underscores the bank’s continued use of virtual participation mechanisms to facilitate shareholder engagement and governance processes.

The most recent analyst rating on (BMA) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on Banco Macro SA stock, see the BMA Stock Forecast page.

Spark’s Take on BMA Stock

According to Spark, TipRanks’ AI Analyst, BMA is a Neutral.

Banco Macro’s overall stock score reflects a mix of strong revenue growth and a solid balance sheet, tempered by modest profitability and significant challenges highlighted in the recent earnings call. Technical indicators show positive momentum, but the financial performance and earnings call concerns weigh heavily on the score.

To see Spark’s full report on BMA stock, click here.

More about Banco Macro SA

Banco Macro SA, operating as Macro Bank Inc., is an Argentine financial institution headquartered in Buenos Aires. It provides a broad range of banking and financial services, with a focus on retail and commercial clients in the local market, and its shares are registered with the U.S. Securities and Exchange Commission as a foreign private issuer.

Average Trading Volume: 290,113

Technical Sentiment Signal: Buy

Current Market Cap: $6.05B

For a thorough assessment of BMA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.